21563-73-5

Usage

Uses

Used in Pharmaceutical Industry:
Benzoyl chloride, 2-amino(9CI) is used as a reagent for the synthesis of various pharmaceutical compounds. Its ability to introduce the benzoyl group to different substrates makes it a valuable component in the development of new drugs and medications.
Used in Dye Industry:
In the dye industry, Benzoyl chloride, 2-amino(9CI) is utilized as a reagent for the production of various dyes. The benzoyl group introduced by Benzoyl chloride, 2-amino- (9CI) contributes to the color and properties of the resulting dyes.
Used in Polymer Industry:
Benzoyl chloride, 2-amino(9CI) is employed as a reagent in the synthesis of polymers. The benzoyl group can be incorporated into the polymer structure, affecting its properties and performance.
Used in Agrochemical Industry:
As an intermediate in the synthesis of agrochemicals, Benzoyl chloride, 2-amino(9CI) plays a crucial role in the development of various agricultural chemicals, such as pesticides and herbicides.
Used in Fine Chemicals Industry:
Benzoyl chloride, 2-amino(9CI) is also used in the synthesis of other fine chemicals, where its reactivity and ability to introduce the benzoyl group are valuable for creating specific chemical structures and properties.

Upstream product

• 118-92-3 anthranilic acid 
• 1445-73-4 1-Methyl-4-piperidone 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 3612-18-8 N-ethyl-4-piperidone 
• 552-16-9 ortho-nitrobenzoic acid 
• 134-20-3 2-carbomethoxyaniline 

Downstream Products

• 4425-23-4 7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-12-one 
• 108296-06-6 2-Amino-N-(6-thiazolidin-3-yl-hexyl)-benzamide 
• 76854-95-0 2-amino-N,N-diethylbenzamide 
• 108319-40-0 2-{[6-(2-Amino-benzylamino)-hexyl]-methyl-amino}-ethanethiol 
• 1261479-23-5 4-[1-(2-aminobenzoyl)-1H-benzoimidazol-2-yl]benzenesulfonic acid 
• 28144-70-9 anthranilic acid amide 
• 1384384-93-3 C₂₂H₁₉ClN₄O₃S 
• 39630-24-5 [2-(morpholin-4-ylcarbonyl)phenyl]amine 
• 56814-10-9 2-amino-N-propylbenzamide 
• 491856-82-7 8-hydroxyquinoline,anthranilic acid 
• 39511-95-0 2-Amino-N-(2-fluorophenyl)benzamide 
• 926209-84-9 C₁₃H₁₀ClFN₂O 
• 102630-80-8 2-Amino-N-(2,5-dimethyl-phenyl)-benzamide 
• 70083-21-5 2-amino-N-(2-methoxyphenyl)benzamide 

Relevant academic research and scientific papers

Synthesis of substituted 1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines

Synthesis of the substituted compounds 9-14 (2-Me or 2-Et; 6-H, 6-OMe or 6-OH; 9-NHR) is reported.

Phenazine derivatives with anti-inflammatory activity from the deep-sea sediment-derived yeast-like fungus cystobasidium laryngis IV17-028

Three new phenazine derivatives (1-3), along with known compounds (4-7) of saphenic acid derivatives, were isolated from a deep-sea sediment-derived yeast-like fungus Cystobasidium larynigs collected from the Indian Ocean. The structures of the new compou

2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F420)-Dependent Nitroreductase (Ddn)

Swapping the substituents in positions 2 and 4 of the previously synthesized but yet undisclosed 5-cyano-4-(methylthio)-2-arylpyrimidin-6-ones 4, ring closure, and further optimization led to the identification of the potent antitubercular 2-thio-substituted quinazolinone 26. Structure-activity relationship (SAR) studies indicated a crucial role for both meta-nitro substituents for antitubercular activity, while the introduction of polar substituents on the quinazolinone core allowed reduction of bovine serum albumin (BSA) binding (63c, 63d). While most of the tested quinazolinones exhibited no cytotoxicity against MRC-5, the most potent compound 26 was found to be mutagenic via the Ames test. This analogue exhibited moderate inhibitory potency against Mycobacterium tuberculosis thymidylate kinase, the target of the 3-cyanopyridones that lies at the basis of the current analogues, indicating that the whole-cell antimycobacterial activity of the present S-substituted thioquinazolinones is likely due to modulation of alternative or additional targets. Diminished antimycobacterial activity was observed against mutants affected in cofactor F420 biosynthesis (fbiC), cofactor reduction (fgd), or deazaflavin-dependent nitroreductase activity (rv3547), indicating that reductive activation of the 3,5-dinitrobenzyl analogues is key to antimycobacterial activity.

NaNO2/I2 as an alternative reagent for the synthesis of 1,2,3-benzotriazin-4(3H)-ones from 2-aminobenzamides

An efficient transformation of 2-aminobenzamides to 1,2,3-benzotriazin-4(3H)-ones in the presence of sodium nitrite (NaNO2) and Iodine (I2) is described. The reaction is proposed to proceed via formation of nitrosyl halide that induces nitrosylation of the amino group of 2-aminobenzamide leading to diazotization followed by intramolecular cyclization.

TBHP as Methyl Source under Metal-Free Aerobic Conditions To Synthesize Quinazolin-4(3H)-ones and Quinazolines by Oxidative Amination of C(sp3)–H Bond

tert-Butyl hydroperoxide (TBHP) served as the methyl source under metal-free aerobic conditions in the oxidative amination of the C(sp3)–H bond to synthesize quinazolin-4(3H)-ones and quinazolines from 2-aminobenzamides and 2-carbonyl-substituted anilines, respectively.

Novel deoxyvasicinone derivatives as potent multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation

A series of multitarget ligands was designed by introducing several structurally diverse aminoacetamide groups at position 6 of the deoxyvasicinone group, with the aim of obtaining novel multifunctional anti-Alzheimer's disease agents using deoxyvasicinone as the substrate. In vitro studies showed that almost all of the derivatives were potent inhibitors of human recombinant acetylcholinesterase (hAChE) and human serum butyrylcholinesterase (hBChE), with IC50 values in the low nanomolar range, and exhibited moderate to high inhibition of Aβ1?42 self-aggregation. In particular, compounds 12h, 12n, and 12q showed promising inhibitory activity for hAChE, with IC50 values of 5.31 ± 2.8, 4.09 ± 0.23, and 7.61 ± 0.53 nM, respectively. Compounds 12h and 12q also exhibited the greatest ability to inhibit hBChE, with IC50 values of 4.35 ± 0.32 and 2.35 ± 0.14 nM, respectively. Moreover, enzyme kinetics confirmed that compound 12q caused a mixed type of AChE inhibition, by binding to both the active sites (PAS and CAS) of AChE. Remarkably, compound 12q also demonstrated the highest potential inhibitory activity for Aβ1?42 self-aggregation (63.9 ± 4.9%, 10 μM), and it was also an excellent metal chelator.

Heavily Substituted Atropisomeric Diarylamines by Unactivated Smiles Rearrangement of N-Aryl Anthranilamides

Diarylamines find use as metal ligands and as structural components of drug molecules, and are commonly made by metal-catalyzed C?N coupling. However, the limited tolerance to steric hindrance of these couplings restricts the synthetic availability of more substituted diarylamines. Here we report a remarkable variant of the Smiles rearrangement that employs readily accessible N-aryl anthranilamides as precursors to diarylamines. Conformational predisposition of the anthranilamide starting material brings the aryl rings into proximity and allows the rearrangement to take place despite the absence of electron-withdrawing substituents, and even with sterically encumbered doubly ortho-substituted substrates. Some of the diarylamine products are resolvable into atropisomeric enantiomers, and are the first simple diarylamines to display atropisomerism.

INDOLE CARBOXAMIDE COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Discovery and characterization of 2-(cyclopropanesulfonamido)-n-(2-ethoxyphenyl)benzamide, ML382: A potent and selective positive allosteric modulator of MrgX1

Previous studies have shown that the activation of mouse MrgC11, a G-protein-coupled receptor, by its peptide ligand BAM8-22 can inhibit chronic pain. A large-scale screen has been carried out to isolate small-molecule allosteric agonists of MrgX1, the human homologue of MrgC11. The goal of this study is to improve the efficacy and potency of positive allosteric modulators (PAMs) with therapeutic implications in combating chronic pain. Herein we report an iterative parallel synthesis effort and a structure-activity relationship study of a series of arylsulfonamides which led to the discovery of the first PAM of MrgX1, ML382.

Intramolecular metal-free oxidative aryl-aryl coupling: An unusual hypervalent-iodine-mediated rearrangement of 2-substituted n-phenylbenzamides

Hypervalent-iodine-mediated oxidative coupling of the two aryl groups in either 2-acylamino-N-phenyl-benzamides or 2-hydroxy-N-phenylbenzamides, with concomitant insertion of the ortho-substituted N or O atom into the tether, has been described for the first time. This unusual metal-free rearrangement reaction involves an oxidative C(sp2)?C(sp2) aryl-aryl bond formation, cleavage of a C(sp2)?C(O) bond, and a lactamization/lactonization. Furthermore, unsymmetrical diaryl compounds can be easily obtained by removing the tether within the cyclized product.